Clinical Scorecard: Innovations in the Management of Pancreatic Cancer

At a Glance

Key Highlights

• MRI provides superior sensitivity over CT for detecting liver lesions and detailed tissue characterization, aiding staging and surgical planning.
• Borderline resectable pancreatic cancer requires careful assessment of vascular involvement to guide surgical versus nonsurgical ablative therapy decisions.
• Multidisciplinary tumor boards facilitate individualized treatment planning incorporating novel systemic therapies, MR-guided radiation, minimally invasive surgery, and irreversible electroporation.

Guideline-Based Recommendations

Diagnosis

• Use high-quality MRI with experienced radiologists for staging pancreatic cancer to assess tumor extent and vascular involvement.
• Perform endoscopic ultrasound-guided biopsy to confirm adenocarcinoma diagnosis.
• Stage disease with cross-sectional imaging to rule out metastatic spread, particularly to the liver.

Management

• Consider neoadjuvant systemic therapy for borderline resectable pancreatic cancer to improve margin-negative resection rates.
• Select systemic therapies based on patient performance status and tumor characteristics.
• Employ local ablative therapies such as irreversible electroporation for unresectable tumors.
• Utilize minimally invasive surgical approaches when feasible.

Monitoring & Follow-up

• Monitor tumor markers such as CA 19-9 and CEA to assess treatment response.
• Repeat imaging post-therapy to evaluate tumor response and resectability status.

Risks

• Risk of positive surgical margins in borderline resectable disease if upfront surgery is performed without neoadjuvant therapy.
• Potential complications related to invasive procedures including biopsy, surgery, and ablative therapies.
• Disease progression during systemic therapy necessitating treatment plan reassessment.

Patient & Prescribing Data

Patients with pancreatic adenocarcinoma across resectability spectrum

Treatment selection is individualized based on tumor staging, vascular involvement, and patient performance status; multidisciplinary input optimizes outcomes.

Clinical Best Practices

• Incorporate multidisciplinary tumor board discussions for all pancreatic cancer cases to tailor treatment plans.
• Utilize MRI as a complementary or preferred imaging modality for detailed staging and surgical planning.
• Apply NCCN guidelines for defining resectability and guiding neoadjuvant therapy decisions.
• Normalize bilirubin and optimize patient performance status prior to initiating systemic or surgical treatments.

References

• NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma